Evidence map›Paper›PMID 42358068›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2026

Addressing the Challenges of Translating LRRK2 Biology into Disease-Modifying Therapies: The LRRK2 Investigative Therapeutics Exchange Initiative.

Esther Sammler, Francesca Tonelli, Michelle Durborow, Jim McNasby, Todd Sherer, Mahmood Ahmed, Stevan W Djuric, Kalpana Merchant, Alastair Reith, Darryle Schoepp and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Esther SammlerMRC Protein Phosphorylation and Ubiquitylation Unit, Faculty of Life Sciences, University of Dundee, Dundee, United Kingdom.ORCID https://orcid.org/0000-0003-3218-7116
Francesca TonelliMRC Protein Phosphorylation and Ubiquitylation Unit, Faculty of Life Sciences, University of Dundee, Dundee, United Kingdom.
Michelle DurborowThe Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Jim McNasbyThe Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Todd ShererThe Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Mahmood AhmedDundee Drug Discovery Unit, Faculty of Life Sciences, University of Dundee, Dundee, United Kingdom.
Stevan W DjuricDepartment of Pharmacology, University of Virginia, Charlottesville, Virginia, USA.
Kalpana MerchantFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Alastair ReithBreckenfield Consulting Ltd, London, United Kingdom.
Darryle SchoeppIndependent Research Consultant, Ardmore, Pennsylvania, USA.
Christine KleinInstitute of Neurogenetics, University of Luebeck, Luebeck, Germany.
Shalini PadmanabhanThe Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Dario R AlessiMRC Protein Phosphorylation and Ubiquitylation Unit, Faculty of Life Sciences, University of Dundee, Dundee, United Kingdom.

Funding

Michael J. Fox Foundation for Parkinson's Research MJFF-025924
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42358068
PMCPMC13602276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.